We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

Altimmune Inc. (NASDAQ:ALT) jumped 13% amid takeover speculation for the pharmaceutical firm. There's speculation that the ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

Shares of Altimmune ( NASDAQ: ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors ...

Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing hope in the ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Bullish option flow detected in Altimmune (ALT) with 8,561 calls trading, 3x expected, and implied vol increasing almost 4 points to 114.21%.

William Blair reaffirmed their market perform rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report ...

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.